New Trade for October 20th, 2022

Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.

This golden age is also presenting tremendous opportunities for investors. Biotech stocks offer the potential for substantial long-term returns. The best biotech stocks to buy now boast robust pipelines and already have winning drugs on the market. Our pick for the day ticks all of these boxes.

Dylan Jovine

Tiny Biotech Wins $75 Billion Patent

Cambridge firm proves its possible to “Find & Replace” cancer cells. The Wall Street Journal reports this small biotech is “Transforming Medicine.” No wonder Goldman Sachs & Morgan Stanley have been quietly buying shares. [Get the name of this little-known stock here >>>.]

Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space. 

So far, the company has managed to remain strongly profitable and has continued to expand revenue within the CF market at a steady pace. Suppose management’s plans for expanded approvals for younger cohorts continue to come to fruition over the next few years. In that case, Vertex will eventually be treating as many as 90% of all people with CF.

The company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and genetic hematologic disorders like sickle cell disease. In other words, even if it eventually ultimately corners the entire market for CF therapies, there will still be other growth opportunities.  

One potential catalyst is its partnership with CRISPR Therapeutics (CRSP) in developing gene-editing treatments for two rare blood disorders, which is expected to begin regulatory studies in March 2023. This means investors can look forward to a steadily increasing flow of new revenue and expanded approvals, both of which should support the stock’s price significantly.   

Of 26 analysts offering recommendations for VRTX, 18 give the stocks a Buy rating, and 9 rate it a Hold. There are no Sell ratings. It seems likely that Vertex will reward patient investors as the steadily growing biopharma company seems ripe for expansion for years to come. With company earnings due out on Nov. 1, investors should watch for upgrades to the stock.

You might also like:

Legacy Research:

Millionaire Trader Demonstrates: “The Perfect Trade”

For over 36 years, I have shown tens of thousands of ordinary Americans how to radically change their financial future.

And in just ten seconds, I’ll demonstrate a powerful (yet simple) strategy anyone can use to collect gains of 373% gains in just 8 days –in bullish AND bearish conditions.

You don’t need trading experience… and you can get started with $100 or less.

I’ve agreed to an interview, where I’ll demonstrate this trade live –you’ll see exactly how it led to triple-digit gains over 48 timesand double-digit gains over 81 different times.[Click here to watch…]

NEXT: